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Background/Aim. Ghrelin has eﬀects on nutrient intake and growth. The cause of growth retardation in congenital heart disease is
multifactorial. The aim of the present study is to investigate the ghrelin in congenital heart disease and the association of ghrelin
with TNF-α and IL-6. Materials and methods. We measured serum ghrelin and TNF-α, and IL-6 levels using speciﬁc immunoassay
in 68 patients (47 acyanotic, 21 cyanotic with congenital heart disease) and in 25 control subjects. Results. In comparison to
controls, serum ghrelin, TNF-α levels were signiﬁcantly higher in acyanotic patients and cyanotic patients with congenital heart
disease (P<. 0001). In acyanotic and cyanotic patients with congenital heart disease, there was a positive correlation between
ghrelin and TNF-α (r = .485, P<. 05 and r = .573 , P<. 01, resp.). Conclusion. Serum ghrelin levels are elevated in acyanotic and
cyanotic patients with congenital heart disease. Increased ghrelin levels represent malnutrition and growth retardation in these
patients. The relation of ghrelin with cytokines may be explained by the possible eﬀect of chronic congestive heart failure and
chronic shunt hypoxemia.
Copyright © 2007 Erdal Yilmaz et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Ghrelin, a 28-amino-acide peptide, is a potent stimulator of
growth hormone release that has been implicated in the con-
trol of food intake and energy homeostasis in human begins
and rodents [1–5]. Ghrelin is mainly produced in the stom-
ach. Ghrelin is not secreted into the gastrointestinal tract like
digestiveenzymesbutintobloodvesselstocirculatethrough-
out the body [6]. Ghrelin causes weight gain by increasing
food intake and reducing fat use [7, 8]. Ghrelin has eﬀects
on nutrient intake and growth hormone (GH) release, sub-
sequently on physical development and growth [9].
Tumor necrosis factor α (TNF-α) and interleukin-6 (IL-
6) are pleiotropic cytokines with numerous immunologic
and metabolic actions [10, 11]. IL-6 is generally considered
to be an important cytokine in the network of cytokines that
regulate immune reactions and acute phase responses [12].
The relationship between congenital heart disease
(CHD), malnutrition, and growth retardation is well docu-
mented [13]. Infants with congenital heart disease are prone
to malnutrition for several reasons including decreased en-
ergy intake, increased energy requirements, or both. Diﬀer-
ent types of cardiac malformations can aﬀect nutrition and
growth to varying degrees [14]. Although nutritional and
growthstatuswereinvestigatedinchildrenwithcyanoticand
acyanotic heart disease, serum ghrelin levels have not been
established. The objective of this study is to investigate and
compare the functional role of ghrelin on the regulation of
energy balance in children with cyanotic and acyanotic con-
genitalheartdiseaseandtheassociationofghrelinwithTNF-
α, IL-6, that were not entirely conﬁrmed in literature by now.
2. MATERIAL AND METHODS
2.1. Studypopulation
The study was conducted on 47 children with acyanotic
CHD, 21 children with cyanotic CHD, and 25 healthy chil-
dren. All patients’ cardiac diagnoses were made on the ba-
sis of clinical and laboratory examinations. None of the pa-
tients had associated abnormalities or pulmonary hyperten-
sion. Body mass index (BMI) was calculated as the ratio of
body weight (kg) and squared height (m). The local ethics2 Mediators of Inﬂammation
Table 1: Age and anthropometric data of the patients and the control subjects.
Cyanotic patients Acyanotic patients Control
(n = 21) (n = 47) (n = 25)
Age (month) 30.5 ±18.42 8 .4 ±15.63 1 .1 ±15.1
Female/Male ratio 10/11 30/17 15/10
Weight (kg) 9.7 ±7.41 0 .9 ±6.22 1 .2 ±9.9
Height (cm) 76.8 ±26.88 3 .6 ±21.99 8 .4 ±22.9
BMI (kg/m2)1 4 .9 ±21 4 .6 ±2.12 1 .5 ±5.5
Table 2: Diagnosis of the patients.
Diagnosis No.
Cyanotic patients
Tetralogy of Fallot 15
Tricuspid atresia 3
Transposition of great arteries 2
Truncus arteriosus 1
Acyanotic patients
Ventricular septal defect 35
Atrial septal defect 11
Patent ductus arteriosus 1
committee approved the study protocol. Informed consents
were obtained from the parents of the subjects.
2.2. Laboratoryinvestigationandimmunoassay
All blood samples were drawn at 08-09 am and stored −20◦C
until the procedure. Serum ghrelin, TNF-α, and IL-6 levels
were analyzed with ELISA kits (TNF-α, IL-6 kit was pur-
chased from Bio-Source International Inc. (Camarillo, Calif,
USA); Ghrelin kit from Phoenix International, Inc, USA).
2.3. Statisticalanalyses
All data were analyzed by SPSS software, version 10.0 for
Windows. Data were presented as mean ± standard de-
viation. The given data were compared between groups
using one-way ANOVA, followed by Post-hoc; Bonferroni
test. Correlation between the parameters were explored with
Spearman’s correlation. P values less than .05 were consid-
ered statistically signiﬁcant.
3. RESULTS
In 47 acyanotic patients, mean age was 30.5 ± 18.4 months,
in21cyanoticpatientswas28.4±15.6monthsandin25c on-
trol subjects was 31.1 ±15.1 months. Age and anthropomet-
ric data of the patients and the control subjects are shown in
Table 1. There was no signiﬁcant diﬀerence between groups
(the acyanotic patients, the cyanotic patients) in terms of
mean age, weight, height, BMI. The speciﬁc cardiac lesions
of patients are listed in Table 2.
Serum ghrelin levels were signiﬁcantly higher than in
acyanotic and cyanotic groups compared to in the control
Table 3: Ghrelin, TNF-α, and IL-6 levels of patients with CHD and
control groups.
Cyanotic patients Acyanotic patients Control
(n = 21) (n = 47) (n = 25)
Ghrelin (ng/ml) 19.2 ±5.9b,c 41.9 ±11.6a 8.6 ±1.7
TNF-α (pg/ml) 11 ±4.1e,f 18.8 ±5.4a 7.5 ±3.4
IL-6 (pg/ml) 16.2 ±6.9b 13.6 ±5.8d 3.2 ±1.4
aP<. 0001 control: acyanotic group
bP<. 0001 control: cyanotic group
cP<. 0001 cyanotic: acyanotic group
dP<. 001 control: acyanotic group
eP<. 001 cyanotic: acyanotic group
fP<. 01 control: cyanotic group
group (P<. 0001) (Table 3). Serum ghrelin levels in the
acyanotic patients were signiﬁcantly higher than in the cyan-
otic patients (P<. 0001). TNF-α levels were signiﬁcantly
higher than in cyanotic and acyanotic patients with CHD
compared to in the control groups (P<. 001, P<. 0001,
resp.). Serum TNF-α values were higher in the acyanotic pa-
tients compared to the cyanotic patients with CHD (P<
.001). Serum IL-6 levels were higher than in cyanotic and
acyanotic patients with CHD compared to in the control
groups (P<. 0001, P<. 001, resp.).
In both acyanotic and cyanotic groups, serum ghrelin
levels were negatively correlated with BMI (r =− .549, P<
.05 and r =− .688, P<. 01, resp.) (Figures 1(a) and 1(b)).
IL-6 and TNF-α levels were not related to BMI in the acyan-
oticandcyanoticpatientswithCHD.Ghrelinlevelswerealso
correlated with TNF-α in the acyanotic and cyanotic groups
(r = .485, P<. 05 and r = .573, P<. 01, resp.) (Figures
2(a) and 2(b)). Ghrelin levels were not related to IL-6 in
the acyanotic and cyanotic patients with CHD (r =− .263,
P>. 05 and r = .398, P>. 05, resp.).
4. DISCUSSION
ThecauseofgrowthretardationinCHDismultifactorial.In-
adequatecaloricintake,malabsorption,andincreasedenergy
requirements caused by increased metabolism may all con-
tribute. However, inadequate caloric intake appears to be the
most important cause of growth failure in CHD [13, 15, 16].
Patients with acyanotic heart disease had a greater growth
deﬁcit in weight, and those with cyanotic heart disease had
a greater growth deﬁcit in stature as demonstrated by both
decreased height and weight. Although growth impairment
is most pronounced in infants with cyanotic CHD, growthErdal Yilmaz et al. 3
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Figure 1: (a) Correlation of ghrelin with BMI in acyanotic patients with CHD (r =− .549, P<. 05). (b) Correlation of ghrelin with BMI in
cyanotic patients with CHD (r =− .688, P<. 01).
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Figure 2: (a) Correlation of ghrelin with TNF-α in acyanotic patients with CHD (r = .485, P<. 05). (b) Correlation of ghrelin with TNF-α
in cyanotic patients with CHD (r = .573, P<. 01).
failure does not correlate well with the degree of hypoxia. In
this study, the cyanotic patients had a more pronounced re-
tardationinbothheightandweightthanintheacyanoticpa-
tients [13, 17].
Ghrelin is accepted as a good marker of the nutritional
state, mainly in situations of malnutrition, like anorexia ner-
vosa, owing its fast recovery after weight gain [18]. The in-
verse correlation between ghrelin levels and BMI is well de-
ﬁned [9, 19]. We observed the mentioned correlation, both
in children with cyanotic heart disease and in children with
acyanotic heart disease.
Although the cyanotic patients had a more pronounced
retardation in both height and weight than in the acyanotic
patients, we found that serum ghrelin levels signiﬁcantly el-
evated in the acyanotic patients than in the cyanotic patients
(P<. 0001).Growthfailureincyanoticchildrenhasnotbeen4 Mediators of Inﬂammation
shown to be proportional to the severity of cyanosis, suggest-
ing that multiple factors are involved in the pathogenesis of
their growthdisturbance [20].Alteration ofendocrine medi-
ators of growth has been implicated as a possible mechanism
of growth failure in cyanotic patients. Cyanotic newborn
lambs have decreased levels of serum insulin-like growth fac-
tor I without a corresponding decrease in growth hormone
or hepatic growth factor receptors [21]. Weintraub et al. [22]
reported that while insulin-like growth factor I levels were
linearlyrelatedtoheightandweightinpatientswithcyanotic
lesions, no such correlation was found in their cyanotic pa-
tients. These studies suggest that chronic tissue hypoxia may
have independent role in growth failure.
We found that serum TNF-α signiﬁcantly increased in
the cyanotic patients and in the acyanotic patients. Similarly,
serum IL-6 was increased in both groups but the change was
moredistinctiveinthecyanoticpatients.TNF-αandIL-6ap-
pear to be important cachectic process mediators, although
this association is not completely established [23, 24]. Car-
diac cachexia describes wasting primarily due to loss of lean
body mass. Cachexia results in decreased muscle strength
and function and compromised immune function [25, 26].
Thissyndromeislikelytooccurinchildrenwhohavechronic
congestive heart failure, chronic shunt hypoxemia [27]. In
addition to inadequate calorie and protein intake, there is
evidence that this syndrome may be caused by circulating tu-
mor necrosis factor, which stimulates catabolism [28].
In the present study, ghrelin correlated to positively with
TNF-α, in acyanotic patients and cyanotic patients with
CHD. The relation of ghrelin with TNF-α raises the possi-
bility of the direct eﬀect of TNF-α upon ghrelin or the im-
pact of heart failure severity upon both ghrelin and TNF-α.
Nagaya et al. [29] have shown that plasma ghrelin level is in-
creasedincachecticpatientswithcongestiveheartfailureasa
compensatory mechanism in response to anabolic-catabolic
imbalance.
In conclusion, serum ghrelin level is elevated in cyan-
otic and acyanotic patients with CHD. Increased ghrelin lev-
els represents malnutrition and growth retardation in these
patients. Additionally, the relation of ghrelin with cytokines
may be explained by the possible eﬀect of chronic congestive
heart failure and chronic shunt hypoxemia.
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